Although the food and drug administration (FDA) has generally discouraged development programs focusing narrowly on certain feature of a defined psychiatric syndrome when other drugs in the class are considered to be treatment for the broad syndrome, we have made exceptions when there is a legitimate basis for targeting selected aspects of a psychiatric illness.